BRIEF-Cogent Biosciences Announces Positive Top-Line Results Of APEX Trial Of Bezuclastinib In Patients With Advanced Systemic Mastocytosis

Reuters
Dec 08
BRIEF-<a href="https://laohu8.com/S/COGT">Cogent Biosciences</a> Announces Positive Top-Line Results Of APEX Trial Of Bezuclastinib In Patients With Advanced Systemic Mastocytosis

Dec 8 (Reuters) - Cogent Biosciences Inc COGT.O:

  • COGENT BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE RESULTS OF APEX TRIAL OF BEZUCLASTINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM)

  • COGENT BIOSCIENCES INC - APEX NDA SUBMISSION EXPECTED IN 1H 2026

  • COGENT BIOSCIENCES INC - BEZUCLASTINIB TRIAL SHOWED 89% OF PATIENTS ACHIEVING ≥50% REDUCTION IN BONE MARROW MAST CELLS

Source text: ID:nGNX7299pC

Further company coverage: COGT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10